Lexeo Therapeutics (NASDAQ:LXEO) Given Buy Rating at Chardan Capital

Lexeo Therapeutics (NASDAQ:LXEO)‘s stock had its “buy” rating reaffirmed by investment analysts at Chardan Capital in a report issued on Tuesday,Benzinga reports. They presently have a $25.00 target price on the stock.

A number of other brokerages have also commented on LXEO. Leerink Partners dropped their price target on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research note on Monday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $24.00 target price on shares of Lexeo Therapeutics in a research note on Tuesday, January 21st. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $23.60.

Lexeo Therapeutics Trading Up 50.9 %

Shares of LXEO stock opened at $4.09 on Tuesday. The business has a 50-day moving average of $4.15 and a 200 day moving average of $6.71. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.95 and a quick ratio of 5.95. Lexeo Therapeutics has a 1-year low of $2.32 and a 1-year high of $19.50. The stock has a market capitalization of $135.24 million, a PE ratio of -1.29 and a beta of 3.85.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09. As a group, sell-side analysts anticipate that Lexeo Therapeutics will post -3.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in shares of Lexeo Therapeutics by 86.5% during the third quarter. Geode Capital Management LLC now owns 553,247 shares of the company’s stock valued at $5,003,000 after purchasing an additional 256,635 shares in the last quarter. State Street Corp increased its position in Lexeo Therapeutics by 29.4% during the 3rd quarter. State Street Corp now owns 253,946 shares of the company’s stock valued at $2,296,000 after buying an additional 57,674 shares in the last quarter. Frazier Life Sciences Management L.P. bought a new position in Lexeo Therapeutics during the 3rd quarter valued at approximately $11,307,000. Barclays PLC boosted its holdings in Lexeo Therapeutics by 162.2% in the third quarter. Barclays PLC now owns 50,210 shares of the company’s stock worth $454,000 after acquiring an additional 31,057 shares in the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of Lexeo Therapeutics by 18.9% in the third quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after acquiring an additional 599,203 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.